Effects of Cannabinoids on Emotional States and Alcohol Use Among Underrepresented Groups: Moderation by Perceived Discrimination

IF 1.7 4区医学 Q3 CLINICAL NEUROLOGY

Human Psychopharmacology: Clinical and Experimental Pub Date : 2025-09-07 DOI:10.1002/hup.70016

Renée Martin-Willett, Carillon J. Skrzynski, Angela D. Bryan, L. Cinnamon Bidwell

{"title":"Effects of Cannabinoids on Emotional States and Alcohol Use Among Underrepresented Groups: Moderation by Perceived Discrimination","authors":"Renée Martin-Willett, Carillon J. Skrzynski, Angela D. Bryan, L. Cinnamon Bidwell","doi":"10.1002/hup.70016","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study examined the effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) on negative mood and drinking behaviors, and whether those effects were moderated by levels of perceived discrimination among participants who identify with a racial, ethnic, gender, or sexual identity that is underrepresented in research.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Participants were either not using cannabis, using cannabis with THC, or using cannabis with CBD and were assessed at baseline, 2 weeks, and 4-weeks following <i>ad libitum</i> use of a legal market cannabis product that was randomly assigned to them. Primary outcomes included scores on the Depression Anxiety Stress (DASS) Scale and number of drinking days. Moderation analyses used the Perceived Discrimination Scale (PDS).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>172 participants who were 62% female and mean age = 30.2 were included (not using cannabis = 20, using cannabis = 152; of those, THC = 96, CBD = 56). There were significant changes in DASS scores over time, with participants using CBD experiencing greater decreases in symptoms versus participants using THC. There was also a marginal conditionXtimeXPDS interaction that was significant when the condition not using cannabis was removed from the analysis. In this case, participants in the CBD and THC conditions shared a general linear trend of decreasing DASS total scores over time, but only at average (mean) and high (+1 SD) levels of PDS scores. There were no significant effects on alcohol-related outcomes.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>CBD may be helpful in reducing negative emotional symptoms in the short term without increasing risk for disordered alcohol use, and perceived discrimination plays a significant role in this relationship.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>Clinicaltrials. gov (NCT03491384; Registration Date 2018-02-28); Open Science Framework</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"40 5","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2025-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.70016","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

This study examined the effects of tetrahydrocannabinol (THC) and cannabidiol (CBD) on negative mood and drinking behaviors, and whether those effects were moderated by levels of perceived discrimination among participants who identify with a racial, ethnic, gender, or sexual identity that is underrepresented in research.

Methods

Participants were either not using cannabis, using cannabis with THC, or using cannabis with CBD and were assessed at baseline, 2 weeks, and 4-weeks following ad libitum use of a legal market cannabis product that was randomly assigned to them. Primary outcomes included scores on the Depression Anxiety Stress (DASS) Scale and number of drinking days. Moderation analyses used the Perceived Discrimination Scale (PDS).

Results

172 participants who were 62% female and mean age = 30.2 were included (not using cannabis = 20, using cannabis = 152; of those, THC = 96, CBD = 56). There were significant changes in DASS scores over time, with participants using CBD experiencing greater decreases in symptoms versus participants using THC. There was also a marginal conditionXtimeXPDS interaction that was significant when the condition not using cannabis was removed from the analysis. In this case, participants in the CBD and THC conditions shared a general linear trend of decreasing DASS total scores over time, but only at average (mean) and high (+1 SD) levels of PDS scores. There were no significant effects on alcohol-related outcomes.

Conclusions

CBD may be helpful in reducing negative emotional symptoms in the short term without increasing risk for disordered alcohol use, and perceived discrimination plays a significant role in this relationship.

Trial Registration

Clinicaltrials. gov (NCT03491384; Registration Date 2018-02-28); Open Science Framework

查看原文本刊更多论文

大麻素对代表性不足群体的情绪状态和酒精使用的影响：通过感知歧视来调节

本研究考察了四氢大麻酚（THC）和大麻二酚（CBD）对负面情绪和饮酒行为的影响，以及这些影响是否会因研究中未被充分代表的种族、民族、性别或性身份的参与者感知到的歧视水平而被缓和。方法参与者要么不使用大麻，要么使用含四氢大麻酚的大麻，要么使用含CBD的大麻，并在随意使用随机分配给他们的合法市场大麻产品后的基线、2周和4周进行评估。主要结果包括抑郁、焦虑、压力（DASS）量表得分和饮酒天数。适度分析使用感知歧视量表（PDS）。结果纳入172名参与者，其中62%为女性，平均年龄为30.2岁（不使用大麻= 20，使用大麻= 152，其中THC = 96, CBD = 56）。随着时间的推移，DASS评分发生了显著变化，与使用四氢大麻酚的参与者相比，使用CBD的参与者症状的减轻幅度更大。当不使用大麻的情况从分析中删除时，还有一个边际条件xtimexpds相互作用是显著的。在这种情况下，CBD和THC条件下的参与者随着时间的推移，DASS总分呈总体线性下降趋势，但仅在PDS得分的平均（平均值）和高（+1 SD）水平上。对酒精相关的结果没有显著影响。结论CBD可能在短期内有助于减少负面情绪症状，而不会增加酒精使用障碍的风险，感知歧视在这一关系中起重要作用。临床试验。gov (NCT03491384；注册日期2018-02-28)；开放科学框架

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Human Psychopharmacology: Clinical and Experimental 医学-精神病学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design